| 1 |
35582188 | Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials. | 2022 Mar 31 |
7 |
| 2 |
34277971 | Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program. | 2021 Jul |
2 |
| 3 |
34836340 | Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome. | 2021 Nov 15 |
2 |
| 4 |
32701600 | Tubular effects of sodium-glucose cotransporter 2 inhibitors: intended and unintended consequences. | 2020 Sep |
2 |
| 5 |
32734255 | SGLT2 Inhibitors for Treatment of Refractory Hypomagnesemia: A Case Report of 3 Patients. | 2020 May-Jun |
2 |
| 6 |
33205810 | SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes. | 2020 Dec 11 |
1 |
| 7 |
28826578 | SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms. | 2018 Jan - Mar |
1 |
| 8 |
27977314 | Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. | 2017 Mar |
1 |
| 9 |
28748724 | Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. | 2017 Oct |
2 |
| 10 |
27628105 | Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. | 2016 Dec |
3 |